Skip to main content

Table 1 Occurrence rate of thrombus (efficacy endpoint)

From: Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery

Efficacy endpoint Rivaroxaban group (case number/total number) Parnaparin group (case number/total number) P value
Primary efficacy endpoint 6/341 (1.7 %) 10/324 (3.1 %) >0.25
Death 0/341 (0.0 %) 1/324 (0.3 %)  
Non-fatal pulmonary embolism 1/341 (0.3 %) 1/324 (0.3 %)  
DVT 6/341 (1.7 %) 8/324 (2.5 %)  
Proximal end 2/341 (0.6 %) 3/324 (0.9 %)  
Distal end only 4/341 (1.2 %) 5/324 (1.5 %)  
Severe VTEa 2/341 (0.6 %) 4/324 (1.2 %) >0.25*
Symptomatic VTEb 3/341 (0.9 %) 6/324 (1.9 %) >0.25*
During the treatment 3/341 (0.9 %) 5/324 (1.5 %)  
During the follow-up 0/277 (0.0 %) 1/268 (0.4 %)  
Death during the follow-up 0/277 (0.0 %) 0/268 (0.0 %)  
  1. *Used the corrected χ 2 test
  2. aSevere VTE was the combined turnover, composing of proximal DVT formation, nonfatal pulmonary embolism, and VTE-induced death
  3. bSymptomatic VTE included any symptomatic DVT formation (proximal or distal) and nonfatal/fatal symptomatic pulmonary embolism